SG11201902940RA - Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same - Google Patents

Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same

Info

Publication number
SG11201902940RA
SG11201902940RA SG11201902940RA SG11201902940RA SG11201902940RA SG 11201902940R A SG11201902940R A SG 11201902940RA SG 11201902940R A SG11201902940R A SG 11201902940RA SG 11201902940R A SG11201902940R A SG 11201902940RA SG 11201902940R A SG11201902940R A SG 11201902940RA
Authority
SG
Singapore
Prior art keywords
international
adjuvants
engeneic
sirius
pty
Prior art date
Application number
SG11201902940RA
Inventor
Himanshu Brahmbhatt
Jennifer Macdiarmid
Original Assignee
Engeneic Molecular Delivery Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engeneic Molecular Delivery Pty Ltd filed Critical Engeneic Molecular Delivery Pty Ltd
Publication of SG11201902940RA publication Critical patent/SG11201902940RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1235—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Abstract

PPVOUNV. dsRNA PPP WIM.14 4+9%1AV ( RIG-1) (MDAS) DNA € 1, 0 4 13K ( AIM2 ) cGAMI) ( ASC ) ( TBK ) C casPa- Pro-inflammatory cytokines Mitochondrion Cytosol Endosome IL-0 & IL-18 DNA 'D)00,4 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 12 April 2018 (12.04.2018) WIP0 1 PCT omit VIII °nolo olliolu VIII oloiliono oimIE (10) International Publication Number WO 2018/065923 Al (51) International Patent Classification: A61K 48/00 (2006.01) A61K 47/46 (2006.01) (21) International Application Number: PCT/IB2017/056131 (22) International Filing Date: 04 October 2017 (04.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/405,074 06 October 2016 (06.10.2016) US (71) Applicant: ENGENEIC MOLECULAR DELIVERY PTY LTD [AU/AU]; Building 2, 25 Sirius Road, Lane Cove West, Sydney, New South Wales 2066 (AU). (72) Inventors: BRAHMBHATT, Himanshu; c/o Engeneic Molecular Delivery PTY LTD, Building 2, 25 Sirius Road, Lane Cove West, Sydney, New South Wales 2066 (AU). MACDIARMID, Jennifer; c/o Engeneic Molecular Deliv- ery PTY LTD, Building 2, 25 Sirius Road, Lane Cove West, Sydney, New South Wales 2066 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: BACTERIAL MINICELLS FOR DELIVERING NUCLEIC ACID ADJUVANTS AND METHODS OF USING THE SAME Figure 1 Endosomal receptors Cytosolic receptors (57) : This disclosure provides intact bacterially derived minicells containing nucleic acids adjuvants or plasmids encoding O nucleic acids adjuvants that can produce a desired immune response in target cells. This discosure further provides methods that employ \" minicells to deliver nucleic acids adjuvants for use in the treatment of diseases, including neoplastic disease and cancer. C [Continued on next page] WO 2018/065923 Al MIDEDIM011010EIRDERI0 1111111111111111111111111111111111111111 Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))
SG11201902940RA 2016-10-06 2017-10-04 Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same SG11201902940RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662405074P 2016-10-06 2016-10-06
PCT/IB2017/056131 WO2018065923A1 (en) 2016-10-06 2017-10-04 Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same

Publications (1)

Publication Number Publication Date
SG11201902940RA true SG11201902940RA (en) 2019-05-30

Family

ID=61829954

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201902940RA SG11201902940RA (en) 2016-10-06 2017-10-04 Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same

Country Status (12)

Country Link
US (1) US11485976B2 (en)
EP (1) EP3522935A4 (en)
JP (2) JP7213798B2 (en)
CN (1) CN110022905B (en)
AU (1) AU2017339841A1 (en)
CA (1) CA3039010A1 (en)
EA (1) EA201990689A1 (en)
IL (1) IL265855A (en)
MA (1) MA46469A (en)
SG (1) SG11201902940RA (en)
TW (1) TW201828994A (en)
WO (1) WO2018065923A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7029957B2 (en) * 2014-10-03 2022-03-04 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド Improved filling of small molecule compounds in intact bacterial vesicles
CN112689511A (en) * 2018-07-23 2021-04-20 安吉尼科分子传输公司 Compositions comprising minicells of bacterial origin and methods of use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
WO1998041628A1 (en) 1997-03-19 1998-09-24 Zymogenetics, Inc. Secreted salivary zsig32 polypeptides
US6747002B2 (en) 1999-05-11 2004-06-08 Ortho-Mcneil Pharmaceutical, Inc. Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
JP4458846B2 (en) 2001-10-15 2010-04-28 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド Complete minicells as vectors for DNA transfer and gene therapy in vitro and in vivo
ES2734652T3 (en) * 2002-04-04 2019-12-11 Zoetis Belgium S A Immunostimulatory oligonucleotides containing G and U
JP2006512391A (en) * 2002-12-30 2006-04-13 スリーエム イノベイティブ プロパティズ カンパニー Combination immunostimulant
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
PL1694361T3 (en) 2003-12-09 2011-08-31 Engeneic Molecular Delivery Pty Ltd Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells
PT1718338E (en) 2004-02-02 2015-09-21 Engeneic Molecular Delivery Pty Ltd Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
US8772013B2 (en) * 2004-02-02 2014-07-08 Engeneic Molecular Delivery Pty Ltd Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
MX2007002294A (en) * 2004-08-26 2007-10-19 Engeneic Molecular Delivery Pty Ltd Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells.
EP2040725B1 (en) 2006-06-23 2014-01-15 EnGeneIC Molecular Delivery Pty Ltd. Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
DK2865755T3 (en) 2007-03-30 2017-05-15 Engeneic Molecular Delivery Pty Ltd BACTERIAL DERIVATIVE INTACT MINICELLS WITH REGULATORY RNA
ES2620748T3 (en) * 2010-06-25 2017-06-29 Idera Pharmaceuticals, Inc. New toll 3 receptor agonists and procedures for their use
JP5871212B2 (en) * 2010-07-28 2016-03-01 国立大学法人北海道大学 Novel nucleic acid having adjuvant activity and use thereof
JP6199746B2 (en) * 2011-02-15 2017-09-20 バキシオン セラピューティクス，リミテッド ライアビリティ カンパニー Bacterial minicell therapeutic compositions and methods for targeted delivery of bioactive molecules based on antibodies and Fc-containing targeting molecules
CA2926161C (en) * 2013-10-04 2023-03-14 Engeneic Molecular Delivery Pty Ltd Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma

Also Published As

Publication number Publication date
CN110022905B (en) 2024-02-06
CN110022905A (en) 2019-07-16
EA201990689A1 (en) 2019-10-31
JP7213798B2 (en) 2023-01-27
JP2019533663A (en) 2019-11-21
MA46469A (en) 2019-08-14
WO2018065923A1 (en) 2018-04-12
TW201828994A (en) 2018-08-16
JP2023022207A (en) 2023-02-14
EP3522935A1 (en) 2019-08-14
US11485976B2 (en) 2022-11-01
US20180100159A1 (en) 2018-04-12
AU2017339841A1 (en) 2019-05-02
EP3522935A4 (en) 2020-05-13
IL265855A (en) 2019-06-30
CA3039010A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201803728YA (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
SG11201907299XA (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201900955VA (en) T cell receptors and immune therapy using the same
SG11201808619QA (en) Nucleic acid-polypeptide compositions and uses thereof
SG11201908994RA (en) Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
SG11201811432WA (en) Rna for cancer therapy
SG11201807187XA (en) Binding members to pd-l1
SG11201805217XA (en) Compositions and methods for the treatment of hemoglobinopathies
SG11201908567UA (en) Modified cyclic dinucleotide compounds
SG11201908023YA (en) T cell receptors and immune therapy using the same against prame positive cancers
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201807548SA (en) Inducible binding proteins and methods of use
SG11201803958WA (en) Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201907855QA (en) Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
SG11201908919XA (en) Combination therapies targeting pd-1, tim-3, and lag-3
SG11201903167QA (en) Compounds and methods for reducing atxn3 expression
SG11201806542PA (en) Anti-mica antibodies
SG11201903737PA (en) Neutralizing anti-tl1a monoclonal antibodies
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof